Core Viewpoint - Immuron Limited is an Australian biopharmaceutical company focused on developing orally delivered targeted polyclonal antibodies for treating infectious diseases, with a presentation scheduled at the Coffee Microcaps Conference on March 5, 2026 [1][2]. Company Overview - Immuron Limited trades on ASX as IMC and on NASDAQ as IMRN, specializing in biopharmaceuticals [2]. - The company is dedicated to the commercialization of its products, particularly in the area of infectious diseases [2]. Product Information - **Travelan**: An orally administered passive immunotherapy that reduces the likelihood of travelers' diarrhea, made from hyper-immune bovine antibodies [3]. - **IMM-124E**: Developed from the colostrum of immunized cattle, targeting enterotoxigenic E. coli (ETEC) and produced in tablet form as Travelan [6][8]. - **IMM-529**: An adjunctive therapy for recurrent Clostridioides difficile infection (CDI), targeting multiple virulence components of C. diff [9][10]. - **ProIBS**: A certified medical device for treating irritable bowel syndrome (IBS) symptoms, with a usability study showing 94% of users found it helpful [13]. Market Context - Travelers' diarrhea is a significant health issue, particularly among travelers to lower- and middle-income regions, with military personnel being notably affected [4][16]. - The IBS treatment market in Australia is projected to generate approximately AU$221.14 million in 2025, with an annual growth rate of 3.28% [14].